GlaxoSmithKline (GSK) Price & Analysis

Compare

1,009 Followers

GSK Stock Chart & Stats

Day’s Range― - ―

52-Week Range1,242.50p - 1,678.68p

Previous CloseN/A

Volume367.08K

Average Volume (3M)8.61M

Market Cap

£56.36B

Enterprise Value73.93B

Total Cash (Recent Filing)£3.62B

Total Debt (Recent Filing)£17.35B

Price to Earnings (P/E)16.6

Beta0.80

Next Earnings

Oct 29, 2025

EPS Estimate

0.47

Next Dividend Ex-Date

Aug 14, 2025

Dividend Yield4.17%

Share Statistics

EPS (TTM)0.45

Shares Outstanding4,077,348,600

10 Day Avg. Volume8,578,379

30 Day Avg. Volume8,613,314

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)4.02

Price to Sales (P/S)1.75

P/FCF Ratio15.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,574.50

Price Target Upside13.85% Upside

Rating ConsensusHold

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Strategic FocusGSK's strategic focus on navigating and mitigating tariffs is seen as a positive capability to manage external challenges.

Vaccines SegmentStock movement partly driven by relief that the Vaccines segment performed better than expected.

Bears Say

FDA Advisory CommitteeConcerns exist over the delayed approval process for Blenrep, a key launch for GSK, due to negative advisory committee feedback and the submission of additional data.

Foreign Exchange ImpactsForeign exchange impacts are expected to worsen, offsetting guidance improvements and affecting sales and operating profit.

Sales And EPS GrowthAnalyst maintains an underperform rating for GSK due to slowing sales and EPS growth as key franchises mature or decline.

GlaxoSmithKline News

Trump, pharma industry discuss increasing medicine spending abroad, Reuters says

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and...

3h ago

AZN

BMY

GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on...

6h ago

GSK

PFE

Trump Weekly: President says raising tariffs on India ‘substantially’

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

3d ago

AEO

Trump says separate tariff announcements coming for semi chips, pharmaceuticals

President Donald Trump said while being interviewed on CNBC that separate tariff announcements are coming within the next...

3d ago

AMD

GSK price target lowered to 1,400 GBp from 1,460 GBp at JPMorgan

JPMorgan lowered the firm’s price target on GSK (GSK) to 1,400 GBp from 1,460 GBp and keeps an...

4d ago

GSK

Trump posts letters calling on drug company CEOs to lower prices

Letters were sent to the CEOs of AbbVie (ABBV), Boehringer Ingelheim, Bristol Myers Squibb (BMY), Novartis (NVS), Gilead...

8d ago

AZN

BMY

Press Secretary says Trump sent letters today to pharmaceutical companies

Press Secretary Karoline Leavitt announced during a media briefing at the White House that President Trump has signed...

8d ago

AZN

BMY

GSK reports Q2 core EPS 46.5p, up 15% at CER

Total Q2 2025 sales GBP 8.0 billion +1% AER; +6% CER. Emma Walmsley, Chief Executive Officer, GSK (GSK)...

9d ago

GSK

GSK revises FY25 guidance at CER, with core EPS towards top end 6%-8%

GSK (GSK) revises its full-year 2025 guidance at constant exchange rates. GSK expects its turnover to increase towards...

9d ago

GSK

Trump administration mulls charging patent holders 1%-5% fee, WSJ reports

The White House is weighing a plan to raise tens of billions of dollars with a new fee...

11d ago

AZN

BMY

GSK Advances Share Buyback Program with Latest Purchase

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GlaxoSmithKline (GSK) has announced the purchase of 502,466 of its...

10h ago

GSK Secures $370 Million Settlement in mRNA Patent Dispute

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has announced a settlement with CureVac and...

10h ago

GSK’s New Study on GSK5764227: A Potential Game-Changer in Gastrointestinal Cancer Treatment

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is conducting...

24h ago

GSK

GSK’s MenABCWY Vaccine Study: A Potential Game-Changer in Meningococcal Disease Prevention

GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is conducting...

24h ago

GSK

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest share price was 1242.50p and its highest was 1678.68p in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is £56.36B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 82 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Quarterly dividend of 16p which represents an annual dividend yield of 4.17%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 0.47.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 4,077,348,600 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.597%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GB:GSK

GlaxoSmithKline Stock Smart Score

Neutral

Fundamentals

Return on Equity

23.47%

Trailing 12-Months

Asset Growth

2.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading global healthcare company that operates in the pharmaceutical, vaccines, and consumer healthcare sectors. The company is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. GSK's core products include a range of prescription medicines, vaccines, and consumer health products spanning across various therapeutic areas such as respiratory, oncology, and infectious diseases.

GlaxoSmithKline (GSK) Earnings & Revenues

Historic Earnings Reports

GSK Stock 12 Month Forecast

Average Price Target

1,574.50p

▲(13.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1289":"1,289p","1730":"1,730p","2171":"2,171p","1509.5":"1,509.5p","1950.5":"1,950.5p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1574.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.57K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.29K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1289,1509.5,1730,1950.5,2171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1456,1515.5,1575,1634.5,1694,1753.5,1813,1872.5,1932,1991.5,2051,2110.5,{"y":2170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1410.1923076923076,1423.8846153846155,1437.576923076923,1451.2692307692307,1464.9615384615386,1478.6538461538462,1492.3461538461538,1506.0384615384614,1519.7307692307693,1533.423076923077,1547.1153846153845,1560.8076923076924,{"y":1574.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1396.5,1388.3076923076924,1380.1153846153845,1371.923076923077,1363.7307692307693,1355.5384615384614,1347.3461538461538,1339.1538461538462,1330.9615384615386,1322.7692307692307,1314.576923076923,1306.3846153846155,1298.1923076923076,{"y":1290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1460.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1595.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1470.49,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1371.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1310.96,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1315.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1373.02,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1449.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1451.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1445.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1517,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1412.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1396.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >